IPRAMAX 25/MG FC TAB 60/FC TAB

Indications

Approved Uses

Epilepsy (partial-onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome), Migraine prophylaxis

Off-Label Uses

Off‑label examples: weight loss/obesity management (often in combination regimens), binge‑eating disorder, alcohol use disorder, neuropathic pain, and some psychiatric indications (e.g., PTSD or mood stabilization) with variable evidence.

Dosage & Administration

Dosing by Condition

Epilepsy (adjunct, adults): start 25-50 mg/day, increase by 25-50 mg/week; usual maintenance 200-400 mg/day in 2 divided doses. Epilepsy (monotherapy, adults/≥10 years): start 25 mg at night (or 25 mg twice daily per some protocols), titrate weekly; usual maintenance ~100-200 mg twice daily (200-400 mg/day). Migraine prophylaxis (adults): start 25 mg nightly, increase by 25 mg/week to 50 mg twice daily (100 mg/day) as typical target; some patients may require up to 200 mg/day.

Initial Dose

Epilepsy: 25 mg twice daily. Migraine Prevention: 25 mg once daily in the evening.

Maintenance Dose

Epilepsy: 200-400 mg/day in two divided doses. Migraine Prevention: 100 mg/day in two divided doses.

Maximum Dose

Epilepsy: usual maximum 400 mg/day (adjunct/monotherapy depending on indication); Migraine prophylaxis: 100 mg/day (50 mg twice daily).

Children's Dosage

Epilepsy (≥2 years): Initial 1-3 mg/kg/day at night for 1 week, then increase by 1-3 mg/kg/week; Maintenance 5-9 mg/kg/day in 2 divided doses. Migraine prophylaxis: Not approved under 12 years

How to Take

Swallow the film‑coated tablet whole with water; may be taken with or without food. Do not crush or chew (may cause bitter taste and is not intended to be chewed).

Side Effects

Common Side Effects

Common: paresthesia, fatigue, dizziness, somnolence/drowsiness, cognitive slowing (attention/memory problems), speech/language problems, nausea/diarrhea, decreased appetite/anorexia, weight loss; may also cause ataxia and visual disturbances (e.g., diplopia).

Safety & Warnings

Contraindications

Contraindication: hypersensitivity to topiramate or any excipients.

Warnings & Precautions

Monitor for suicidal ideation/mood changes; counsel on acute visual symptoms (acute myopia/angle-closure glaucoma-urgent evaluation and discontinue if suspected); monitor for decreased sweating/hyperthermia (esp. children, hot weather); monitor serum bicarbonate for metabolic acidosis; encourage hydration to reduce kidney stones; warn about cognitive/psychomotor slowing; watch for hyperammonemia with valproate; avoid abrupt withdrawal; ensure effective contraception and discuss pregnancy risks.

Age Restriction

Epilepsy: approved for patients ≥2 years; Migraine prophylaxis: approved for patients ≥12 years (not approved <2 years for seizures or <12 years for migraine prevention).

Driving Warning

May Cause Drowsiness

Drug Interactions

Drug Interactions

Key interactions: valproate (hyperammonemia/encephalopathy risk); phenytoin/carbamazepine (↓ topiramate levels; phenytoin levels may ↑); oral contraceptives (reduced efficacy mainly at ≥200 mg/day); other carbonic anhydrase inhibitors (↑ metabolic acidosis/kidney stones); CNS depressants/alcohol (additive CNS effects); hydrochlorothiazide (↑ topiramate levels); lithium (levels may change-monitor); metformin (↑ metabolic acidosis risk).

Interaction Severity

MAJOR/clinically significant: valproate (hyperammonemia/encephalopathy ± hypothermia), carbonic anhydrase inhibitors (e.g., acetazolamide) or other acidosis/stone‑promoting drugs (↑ metabolic acidosis/nephrolithiasis risk). MODERATE: estrogen‑containing oral contraceptives (reduced ethinyl estradiol at higher topiramate doses, typically ≥200 mg/day), CNS depressants/alcohol (additive impairment), enzyme inducers phenytoin/carbamazepine (↓ topiramate levels; topiramate may also affect phenytoin in some patients), hydrochlorothiazide (↑ topiramate exposure).

Food Interaction

No clinically significant food restriction; may be taken with or without food.

Alcohol Interaction

Avoid

Special Populations

Children

Epilepsy (≥2 years): Initial 1-3 mg/kg/day at night for 1 week, then increase by 1-3 mg/kg/week; Maintenance 5-9 mg/kg/day in 2 divided doses. Migraine prophylaxis: Not approved under 12 years

Kidney Impairment

If CrCl <70 mL/min: reduce maintenance dose by ~50% and titrate more slowly; in hemodialysis, a supplemental dose may be needed on dialysis days.

Liver Impairment

No specific routine dose adjustment is defined; use with caution in hepatic impairment and titrate/monitor clinically (clearance may be reduced).

Storage & Patient Advice

Missed Dose

Take the missed dose as soon as remembered; if it is close to the next dose, skip the missed dose and resume the regular schedule-do not double doses.

Stopping the Medicine

Do not stop abruptly; taper gradually over several weeks (commonly at least 2-4 weeks, individualized) to reduce seizure risk/withdrawal effects.

Overdose

Symptoms can include somnolence, dizziness, agitation, diplopia/blurred vision, speech/cognitive disturbance, abdominal pain, hypotension, seizures, and metabolic acidosis; management is urgent supportive care, consider activated charcoal if appropriate, and hemodialysis can enhance removal in severe cases.

Monitoring Requirements

Monitor serum bicarbonate (metabolic acidosis), renal function and hydration/stone risk, weight, and neuropsychiatric status (depression/suicidality); assess urgently for ocular symptoms (acute myopia/secondary angle‑closure glaucoma) and consider ammonia if used with valproate or if encephalopathy suspected.

Pharmacology

Mechanism of Action

Blocks voltage‑dependent sodium channels, enhances GABA‑A-mediated inhibition, antagonizes AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase (notably II and IV).

Onset of Action

Pharmacokinetic onset: peak concentration ~2-3 hours after a dose; clinical effect depends on titration-seizure control may improve within days to weeks after reaching an effective dose, and migraine prevention typically requires ~4-8 weeks at target dose.

Duration of Effect

Elimination half‑life is ~21 hours (longer in renal impairment), supporting once‑ or twice‑daily dosing; clinical dosing is commonly twice daily for immediate‑release formulations.

Half-Life

Approximately 21 hours (typical range ~19-23 hours in adults with normal renal function).

Bioavailability

Oral bioavailability is high, approximately ≥80%.

Metabolism

Minimal metabolism (~20%); primarily via hydroxylation, hydrolysis, and glucuronidation; can induce CYP3A4 and inhibit CYP2C19 (clinically relevant at higher doses/with interacting drugs).

Excretion

Primarily renal; ~70% excreted unchanged in urine (with the remainder as metabolites).

Protein Binding

Low protein binding: ~13-17% (generally reported as ~15%).

Product Information

Available Dosage Forms

Tablet, Sprinkle capsule, Extended-release capsule, Oral solution.

Composition per Dose

Each film-coated tablet: 25 mg topiramate

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Also Used For

Migraine Prevention, Mood Stabilization, Neuropathic Pain, Weight Management, Alcohol Dependence, Binge Eating Disorder

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.